Esperion CFO sells 7,337 shares in routine tax-related stock sale

Rhea-AI Filing Summary

Esperion Therapeutics Chief Financial Officer Sheldon L. Koenig reported a routine stock transaction involving company shares. On 12/17/2025, he sold 7,337 shares of Esperion Therapeutics common stock at a price of $3.667 per share. According to the filing, these shares were sold to cover tax obligations arising from the vesting of restricted stock units. After this sale, Koenig beneficially owned 467,525 shares of Esperion common stock, held directly.

Insider Trade Summary

Net Seller: 7,337 shares

Net Sell 1 txn

Insider Halladay Benjamin

Role Chief Financial Officer

Sold 7,337 shs ($27K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,337	$3.667	$27K

Holdings After Transaction: Common Stock — 467,525 shares (Direct)

Footnotes (1)

1. F1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

FAQ

What insider transaction did Esperion Therapeutics (ESPR) disclose in this filing?

The filing shows that Chief Financial Officer Sheldon L. Koenig sold 7,337 shares of Esperion Therapeutics common stock on 12/17/2025.

At what price were the Esperion Therapeutics (ESPR) shares sold by the CFO?

The shares were sold at a price of $3.667 per share as reported in the transaction table.

How many Esperion Therapeutics (ESPR) shares does the CFO own after this transaction?

After the reported sale, Sheldon L. Koenig beneficially owned 467,525 shares of Esperion Therapeutics common stock, held directly.

Why were the Esperion Therapeutics (ESPR) shares sold in this insider transaction?

The explanation states that the 7,337 shares were sold to satisfy the tax obligation on vested shares of restricted stock units.

What is the role of the reporting person in Esperion Therapeutics (ESPR)?

The reporting person, Sheldon L. Koenig, is identified as an officer of Esperion Therapeutics, serving as Chief Financial Officer.

Is this Esperion Therapeutics (ESPR) insider transaction reported by more than one person?

No. The filing indicates it is a Form filed by One Reporting Person, referring only to Sheldon L. Koenig.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/18/2025 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Halladay Benjamin

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MI 48108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/17/2025		S		7,337(1)	D	$3.667	467,525	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.